Aike Baifa: Co-developed the world's first COPD drug with Scripps

The company announced that it has renewed its joint development cooperation agreement with Scripps Research Institute's Calibr Institute to develop a new targeted drug, AK0705, for the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD).

Under the terms of the agreement, Agco will lead the development of AK0705 and Calibr will provide expertise to co-guide the project. The existing collaboration has identified AK0705 as a preclinical drug candidate (PCC), which is expected to commence clinical studies in 2024 upon completion of the next phase of preclinical development.

"We are pleased to continue working hand-in-hand with Calibr to advance the development of AK0705." Said Dr. Wu Zheng, Chairman and CEO of Aike Baifa. "We have made great progress in our collaborative research, and I am confident that we will fully explore the potential clinical value of AK0705 to provide a highly effective first-of-its-kind treatment for respiratory diseases with significant unmet clinical need, such as COPD."

"Treatment options and options for respiratory diseases caused by chronic inflammation are very limited, and the hundreds of millions of people around the world who suffer from respiratory diseases urgently need new treatments," "Through innovative chemical research, AK0705 has the potential to be a new targeted drug for a variety of respiratory diseases," said Dr. PeterSchultz, chairman and CEO of Scripps Research Institute and Calibr. Ako has been an outstanding partner and we look forward to moving this new drug into clinical trials as soon as possible."

About Aike Baifa

Aike Baifa is an innovative biopharmaceutical company focused on significant unmet clinical needs in children and respiratory diseases. Since its establishment in 2014, the company has a number of core technologies and global patents in the field of innovative drug research and development with new mechanisms of action. Through a research and development model that combines independent research and development with external introduction, the company has developed a highly differentiated and rich product pipeline. The core product, Asivir ®, is the world's leading anti-respiratory syncytial virus (RSV) treatment drug and the first new non-tumor drug to be included in the national breakthrough treatment variety. Asivir ® has submitted an application for NDA to CDE in China. Another product nearing commercialization is AZSTARYS®, a new drug for hyperactivity Disorder (ADHD) that has been approved by the FDA, for which Agco has development and marketing rights in Greater China. The company also has several best-in-class or first-in-class potential new drugs in clinical trials or preclinical development.

About the Calibr and Scripps Research Institute

Calibr is a non-profit translational science research organization dedicated to the development of a new generation of innovative drugs. As part of the Scripps Research Institute in San Diego, Calibr is committed to building innovative research and development partnerships with the pharmaceutical industry. Calibr has built a diverse pipeline of small molecules, peptides, biologic drugs and cell therapies from early-stage drug discovery to near-clinical studies.

The Scripps Research Institute is one of the most influential scientific institutions in the world. As a non-profit research organization, the Scripps Research Institute leverages its deep understanding of the biological sciences to conduct highly innovative research and development in pursuit of breakthroughs at the forefront of medicine and solutions to the world's most pressing health problems. Scripps' education and training program is dedicated to developing outstanding students and postdoctoral fellows into the next generation of top scientists.